Karen Ling - Allergan Plc President

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>AP</div>
AGN -- USA Stock  

Earnings Report: 4th of August 2020  

  President
Ms. Karen Lee Ling is Chief Human Resource Officer of Allergan Plc. Ms. Ling is the Chief Human Resources Officer of Allergan, and has served in this role since July 2014, having served as Senior Vice President and Chief Human Resources Officer at Forest from January 2014 to July 2014, prior to its acquisition by Allergan . Ms. Ling joined Forest from Merck Co., where she served as Senior Vice President, Human Resources for the companys Global Human Health and Consumer Care businesses worldwide beginning in November 2011. Previously, she served as Vice President, Compensation and Benefits at Merck and Group Vice President, Global Compensation Benefits at ScheringPlough . Prior to joining ScheringPlough in 2008, Ms. Ling spent 14 years at Wyeth Pharmaceuticals in various positions of responsibility in human resources and in Wyeths Labour and Employment Department. Before joining Wyeth, Ms. Ling was an attorney at Goldstein and Manello, P.C. in Boston. She is currently a member of the Board of Directors of the Glaucoma Foundation, Inc. and The Jed Foundation
Age: 54  President Since 2014      
862 261 7000  http://www.allergan.com
Ling received her J.D. from Boston University School of Law and a B.A. from Yale University.

Allergan Plc Management Efficiency

Allergan Plc has Return on Asset of (0.0564) % which means that on every $100 spent on asset it lost $0.0564. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Daniel PlewRegeneron Pharmaceuticals
2016
Glenn DavidZoetis Inc
2016
Albert BourlaPfizer Inc
2020
Frank DAmelioPfizer Inc
2018
Ronald JanishPerrigo Company Plc
2015
Umang VohraDr Reddys Laboratories
2013
James MichaudPerrigo Company Plc
2016
John WesolowskiPerrigo Company Plc
2016
Alexander MackenziePfizer Inc
2016
Grainne QuinnPerrigo Company Plc
2016
Joyce LeeZoetis Inc
2012
Clinton LewisZoetis Inc
2018
K RaoDr Reddys Laboratories
2016
Sripada ChandrasekharDr Reddys Laboratories
2013
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Geno GermanoPfizer Inc
2014
Louis YuPerrigo Company Plc
2013
Joseph LaRosaRegeneron Pharmaceuticals
2019
Freda LewisHallPfizer Inc
2010
Saumen ChakrabortyDr Reddys Laboratories
2018
John GrayVertex Pharmaceuticals Incorpor
2019

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Stock Performance Indicators

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Pfizer Inc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page